Possibilities have to be translational in the clinical pipelines. You can't have a valuation based on perceived of what if application scenarios that's not how M&A works. It has to be real and proven from existing assets. And assets = clinical pipelines. Take the emotions out and see that it is just another business decision.
Market Data 
Markets 
AI
